Citi raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $33 from $31 and keeps a Buy rating on the shares. The firm sees the upper end of the company’s 2025 outlook as potentially achievable following the Q3 report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX: